Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343737 | 0.88 | MAPT (0.55) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL13122708 | 0.88 | MAPT (0.50) | MAPTHPGDCNR2CA12CA9 | |
| Quinoline SCHEMBL27606879 | 0.85 | MAPT (0.52) | MAPTHPGDCNR2CDK2CNR1 | |
| SCHEMBL11419219 | 0.84 | MAPT (0.53) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL8671558 | 0.84 | KCNH2 (0.53) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL25223963 | 0.82 | MAPT (0.55) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL27751025 | 0.82 | MAPT (0.55) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL11412120 | 0.81 | CDK2 (0.57) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL5553641 | 0.80 | MAPT (0.63) | MAPTHPGDCNR2CDK2CA12 | |
| SCHEMBL25273843 | 0.80 | MAPT (0.52) | MAPTHPGDCNR2CDK2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4978603-A | Developing an emulsion layer containing a rhodium salt and a preferential grain size using a dihydroxy developer, a sulfite and an indazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1990-12-18 | — | — | US | claimed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| CN-102958918-B | Novel tobacco amide derivatives or its salt | FUJIFILM CORP. (JP) | 2015-12-09 | — | — | CN | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0306833-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-4978603-A | Developing an emulsion layer containing a rhodium salt and a preferential grain size using a dihydroxy developer, a sulfite and an indazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| US-4956263-A | BLACKAND WHITE PHOTOGRAPHIC FILM CONTAINING CONTAINING A HYDRAZINE DERIVATIVE; HIGH CONTRAST; DAYLIGHT USE; ANTISOILANTS; SAFELIGHT SAFETY | FUJI PHOTO FILM CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| US-4221857-A | DEVELOPER COMPRISING SULFITE ION, A DIHYDROXYBENZENE, AND A HYDRAZIDE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | MAPT 2039/4885HPGD 161/4885CNR2 2990/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | MAPT 2759/4885HPGD 139/4885CNR2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.